















MITOCHONDRIAL CYTOPATHY WITH COMMON
MELAS MUTATION PRESENTING AS MULTIPLE
SYSTEM ATROPHY MIMIC
Mitochondrial encephalomyopathy, lactic acidosis,
and stroke-like episodes (MELAS) syndrome1 is one
of the most frequently inherited mitochondrial disor-
ders. MELAS syndrome is a systemic disease with
multiple organ involvement.2 The most common
mutation in MELAS is the m.3243A.G mutation
in the MT-TL1 gene.2
We describe a patient with the m.3243A.G
mutation who presented with only partial clinical
manifestation of MELAS. In addition, our patient
had a multiple system atrophy (MSA) phenotype
due to mitochondrial cytopathy. He was treated with
levodopa, which led to clinical improvement of his
extrapyramidal syndrome.
Case report. In 2012, a 60-year-old white man was
referred for progressive gait abnormalities over the pre-
ceding 10 years. He reported deteriorating unsteady
gait and abnormal fatigue of the lower extremities. Per-
sonal history revealed diabetes (onset at age 31), senso-
rineural hearing loss (dependent on hearing aids), and
longstanding generalized fatigue. Family history was
remarkable for tetraparesis of unknown origin in his
deceased mother.
Examination showed mild cerebellar dysarthria,
left-sided hyperreflexia, atrophic proximal tetraparesis
(shoulder girdle, gluteal muscles, and posterior
thighs), slight ataxia of the left upper limb, and dis-
tally reduced vibration sense of the lower extremities
with positive Romberg test. The combination of atro-
phic paresis, diabetes, sensorineural hearing loss, signs
of multisystemic affection of the CNS, and potential
maternal inheritance led to the clinical suspicion of
mitochondrial cytopathy. Biopsy of the left deltoid
muscle displayed findings compatible with mitochon-
drial myopathy (figure, B–D). MRI of the brain and
the spinal cord showed bilateral calcifications of the
basal ganglia, thalami, nuclei dentati, and the pons
(figure, E and F) as well as infratentorial atrophy
(figure, G). Endocrine dysfunction was ruled out as
an underlying cause of calcifications. Sequencing of
the mitochondrial genome revealed the common
MELAS mutation m.3243A.G in theMT-TL1 gene
(55% heteroplasmy in skeletal muscle and 2% in
blood).
After 3 years of clinical stability, he presented with
deterioration of gait. Examination affirmed disease pro-
gression with a marked cerebellar syndrome (progressive
dysarthria, saccadic dysmetria, bilateral cerebellar ataxia
left . right, and bilateral dysdiadochokinesia left .
right), a pyramidal syndrome (left-sided hyperreflexia,
spasticity, and positive Babinski sign), and an
extrapyramidal syndrome (hypomimia, hypophonia,
bilateral rigidity left. right, camptocormia, and marked
postural instability; figure, A). Gait was ataxic with a spas-
tic component. Neuropsychological screening revealed
mild cognitive deficits (Mini-Mental State Examination:
26/30). CSF showed lactic acidosis with normal levels of
tau, phosphorylated tau, and b-amyloid 1–42. Fluoro-
deoxyglucose PET of the brain further supported the
clinical suspicion of multiple system atrophy with cere-
bellar predominance (MSA-C) (figure, H). Diagnosis of
an MSA mimic, most likely due to mitochondrial cytop-
athy, was made. Reduction of extrapyramidal motor
symptoms (improved walking and faster turns) was
achieved with levodopa medication.
Discussion. The m.3243A.Gmutation in theMT-
TL1 gene encoding the mitochondrial tRNALeu(UUR)
is commonly associated with MELAS. Our patient
only had partial manifestation of this syndrome, but
in addition showed a clinical syndrome suggestive of
MSA-C.
MSA-C is a late-onset, sporadic neurodegenerative
disorder characterized by autonomic failure and cere-
bellar ataxia.3–5 The neuropathologic correlate is
a widespread CNS a-synucleinopathy with neurode-
generative changes in striatonigral or olivopontocer-
ebellar structures. Several conditions are known to
mimic MSA-C including metabolic changes. Among
these, a case series of mitochondrial myopathies iden-
tified a subgroup of patients (11%, 9/85) with move-
ment disorders.6 In addition, another case with
mitochondrial polymerase-g 1 mutation7 is related
to mitochondrial cytopathy.
The patient described here presents with an MSA
mimic due to mitochondrial cytopathy harboring the
common mutation associated with MELAS, although
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presentation with MSA is rare in this context. The pre-
served cognition further argues in favor of a typical
MSA presentation, although the lack of orthostatic
hypotension does not. Given recent findings of
decreased coenzyme Q10 levels in the serum/cerebel-
lum of patients with MSA, it is tempting to speculate
that there is a pathophysiologic link between mito-
chondrial dysfunction andMSA in general. The clinical
course—the neurodegenerative syndrome succeeding
the initial manifestation of myopathy—argues in favor
of this hypothesis.
Overall, our observation widens the spectrum of
phenotypes associated with mitochondrial cytopa-
thies in general, and with MELAS in particular.
Moreover, it shows partial clinical improvement to
levodopa implicating residual integrity of the striatal
receptors.
Thus, mitochondrial diseases should be consid-
ered as differential diagnosis in patients presenting
with an MSA-C phenotype and a family history sug-
gestive of mitochondrial disorder. Consequently,
these patients should be offered testing for mutations
Figure Case presentation
(A) Clinical presentation: 65-year-old patient with a confirmed mitochondrial encephalomyopathy, lactic acidosis, and
stroke-like episodes mutation (m.3243A.G) presented with a multiple system atrophy phenotype with hypomimia, camp-
tocormia, and inner rotation of the left hand as a correlate of a left- . right-sided extrapyramidal syndrome as well as
a cerebellar and pyramidal syndrome. (B–D) Histology: (B) hematoxylin and eosin: ragged red fibers and myophagia (*); (C)
cyclooxygenase/succinic dehydrogenase (COX/SDH) double enzymatic staining; COX-deficient, SDH hyperreactive fibers;
and (D) Oil Red O: neutral fat accumulation (scale bar 50 mm). Both, changes in COX/SDH as well as lipid accumulation
suggest mitochondrial dysfunction. (E–G) MRI of the brain and the cervical spine: T2 fluid-attenuated inversion recovery
images show bilateral signal changes in the basal ganglia, thalami (E), and dentate nuclei (F) (arrow) in the areas of calcifi-
cations, furthermore white matter changes in the periventricular zone (E) as well as cerebellar atrophy (F and G). (H)
Fluorodeoxyglucose PET: transversal PET-CT shows diminished metabolism of the cerebellum as well as calcifications of
the dentate nuclei (arrow).
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associated with mitochondrial dysfunction. Further
studies are needed to reveal the potential link between
MSA and mitochondriopathy.
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